# Tarlox and Sotorasib in Patients With KRAS G12C Mutations

> **NCT05313009** · PHASE1,PHASE2 · TERMINATED · sponsor: **Medical University of South Carolina** · enrollment: 5 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Sotorasib and Tarloxotinib
- **DRUG:** Sotorasib and Tarloxotinib

## Key facts

- **NCT ID:** NCT05313009
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-07
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-12-31
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study drug was discontinued by manufacturer for business reasons.
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05313009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05313009, "Tarlox and Sotorasib in Patients With KRAS G12C Mutations". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05313009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*